Signpath Pharma is a clinical stage company based in Center Valley, PA, with a unique drug development platform that focuses on creating heart-safe drugs. Their innovative CorreQT platform technology mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy.
The company's first clinical application of this technology is LipoCurc, a proprietary liposomal formulation of curcumin that is administered intravenously. LipoCurc has successfully completed Phase 1a and 1b clinical trials, showing no cardiac toxicity and signs of efficacy in end-stage cancer patients. Signpath Pharma is currently enrolling patients for a Phase 2 trial in the treatment of glioblastoma, with the aim of expanding clinical sites to additional locations.
Generated from the website